Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Isenberg, David; Furie, Richard; S. Jones, Nicholas; Guibord, Pascal; Galanter, Joshua; Lee, Chin; G McGregor, Anna; István Tóth, Balázs; Rae, Julie; Hwang, Olivia; Desai, Rupal; Lokku, Armend; Ramamoorthi, Nandhini; A. Hackney, Jason; C. Miranda, Pedro; Angelina de Souza, Viviane; José Jaller-Raad, Juan; Maura Fernandes, Anna; García Salinas, Rodrigo; W. Chinn, Leslie; J. Townsend, Michael; Morimoto, Alyssa; Tuckwell, Katie

doi:10.1002/art.41811

Public

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Published in Arthritis & Rheumatology • May 27, 2021

Authors:

David Isenberg

Richard Furie

Nicholas S. Jones

Abstract

OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter, randomized, placebo-controlled st...

Subject

Placebo

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!